Literature DB >> 3598232

Repeatedly relapsing disseminated histoplasmosis: clinical observations during long-term follow-up.

C V Paya, P E Hermans, R E Van Scoy, R E Ritts, H A Homburger.   

Abstract

We report three patients (followed up for 13, 9, and 12 years) who had multiple episodes of disseminated histoplasmosis. Clinically, all three patients had high yields of positive cultures and all developed corticoadrenal insufficiency; all survived the recurrent relapses. One patient had unilateral progressive panophthalmitis, with ocular cultures positive for Histoplasma capsulatum. These relapses occurred despite conventional treatment with large doses of amphotericin B. Prolonged remissions were associated with using small doses of this drug. One patient had a long-term remission while taking ketoconazole daily for more than four years. These patients did not have conditions associated with immunosuppression. Lymphocyte proliferation to mitogens and, in one patient, to histoplasmin, was markedly reduced at the time of relapse and when tested preceding a relapse. All three patients showed a reversal to normal lymphocyte proliferation at the time of the longest last remission.

Entities:  

Mesh:

Year:  1987        PMID: 3598232     DOI: 10.1093/infdis/156.2.308

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Molecular evidence of recurrent histoplasmosis with 9-year latency in a patient with Addison's disease.

Authors:  Tai-Chung Tseng; Shwu-Jen Liaw; Cheng-Hsiang Hsiao; Cheng-Yi Wang; Li-Na Lee; Tien-Shang Huang; Po-Ren Hsueh
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 2.  Diagnosis and management of histoplasmosis.

Authors:  L J Wheat
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

Review 3.  Histoplasma variation and adaptive strategies for parasitism: new perspectives on histoplasmosis.

Authors:  L G Eissenberg; W E Goldman
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.